Perancangan E-health Kota Cerdas (Studi Kasus : Kota Manado )

Smart city merupakan konsep pengembangan, penerapan, dan implementasi teknologi digital untuk menghubungkan, memonitor, dan mengendalikan berbagai sumber daya yang ada dan diaplikasikan pada sebuah wilayah atau kota. Pada beberapa kota maju di Indonesia pun sudah mengadopsi Konsep smart city untuk efisiensi pelayanan kepada masyarakat yang berkelanjutan. Kota Manado pun mengharapkan hal yang sama, ditinjau dari kebutuhan akan teknologi informasi mulai dari pemerintahan, penyedia jasa, bahkan seluruh komponen masyarakat. Salah satu bidang pengembangan yang penting untuk dikembangkan adalah bidang kesehatan (health), mulai dari pelayanan pasien untuk rawat jalan, pelayanan pasien untuk rawat inap, pelayanan untuk pengambilan obat, bahkan untuk pengurusan surat-menyurat dari puskesmas ke rumah sakit, rumah sakit ke rumah sakit, dan sebaliknya dalam penerapan pada jasa-jasa kesehatan. Penelitian ini pun bertujuan untuk merancang model arsitektur dari aplikasi sistem informasi e-health. Dengan adanya perancangan model arsitektur ini, dapat mempermudah menentukan model dari aplikasi sistem informasi e-health, bahkan dapat juga menjadi tolak ukur untuk implementasi di masa yang akan datang. Tentu semuanya dimulai dari peran pemerintah, dalam hal ini pemerintah kota Manado. Untuk data dan informasi yang berhasil dikumpulkan penulis adalah data proses bisnis setiap penyedia jasa kesehatan dalam bentuk wawancara, kuisioner, dan observasi mulai dari rumah sakit, puskesmas, apotik dan klinik di kota Manado secara langsung. Produk yang dihasilkan dari penelitian ini adalah berupa rancangan model arsitektur e-health mulai dari arsitektur data, arsitektur aplikasi serta arsitektur teknologi yang dipresentasikan dalam bentuk gambar dan diagram

Religious Identity, Religious Attendance, and Parental Control

Using a national sample of adolescents aged 10–18 years and their parents (N = 5,117), this article examines whether parental religious identity and religious participation are associated with the ways in which parents control their children. We hypothesize that both religious orthodoxy and weekly religious attendance are related to heightened levels of three elements of parental control: monitoring activities, normative regulations, and network closure. Results indicate that an orthodox religious identity for Catholic and Protestant parents and higher levels of religious attendance for parents as a whole are associated with increases in monitoring activities and normative regulations of American adolescents

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

Introduction Modeling and simulation of pharmacokinetics and pharmacodynamics has previously been shown to be potentially useful in designing Phase I programs of novel anti-cancer agents that show hematological toxicity. In this analysis, a two-stage model-based trial design was evaluated retrospectively using data from the Phase I program with the aurora kinase inhibitor barasertib. Methods Data from two Phase I trials and four regimens were used (n = 79). Using barasertib-hydroxy QPA plasma concentrations and neutrophil count data from only study 1A, a PKPD model was developed and subsequently used to predict the MTD and a safe starting dose for the other trials. Results The PKPD model based on data from the first study adequately described the time course of neutrophil count fluctuation. The two-stage model-based design provided safe starting doses for subsequent phase I trials for barasertib. Predicted safe starting dose levels were higher than those used in two subsequent trials, but lower than used in the other trial. Discussion The two-stage approach could have been applied safely to define starting doses for alternative dosing strategies with barasertib. The limited improvement in efficiency for the phase I program of barasertib may have been due to the fact that starting doses for the studied phase I trials were already nearly optimal. Conclusion Application of the two-stage model-based trial design in Phase I programs with novel anti-cancer drugs that cause haematological toxicity is feasible, safe, and may lead to a reduction in the number of patient treated at sub-therapeutic dose-levels

Collection of Material Dna Samples From Birds in the Gunung Halimun National Park (Ghnp) for Establishing of Dna Bank

This study was conducted to collect material DNA samples from birds in the Gunung Halimun National Park (GHNP) for establishing of DNA bank.Ciptarasa, Geger Hanjuang and Cikaniki village areas were chosen as sites for sample collections in the GHNP.In order to take the sample from birds, transect lines were established at each site where series of mist nets were operated.The captured birds, both live- and died-birds, were identified. For the living birds, blood and/or shed feathers were taken from the bird prior to releasing.In case of died birds, tissue and liver were collected. The collected samples were transported to genetic laboratory at Zoological Division,Researh Center for Biology (RCB)-LIPI (The Indonesian Institute of Science) and kept in 4°C. In this collection, a total of 411 collected samples were obtained, coming from 25 families and 79 species.The 19-endemic birds were found in GHNP

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

Background The phase I program of anticancer agents usually consists of multiple dose escalation studies to select a safe dose for various administration schedules. We hypothesized that pharmacokinetic and pharmacodynamic (PK–PD) modeling of an initial phase I study (stage 1) can be used for selection of an optimal starting dose for subsequent studies (stage 2) and that a post-hoc PK–PD analysis enhances the selection of a recommended dose for phase II evaluation. The aim of this analysis was to demonstrate that this two-stage model-based design, which does not interfere in the conduct of trials, is safe, efficient and effective. Methods PK and PD data of dose escalation studies were simulated for nine compounds and for five administration regimens (stage 1) for drugs with neutropenia as dose-limiting toxicity. PK–PD models were developed for each simulated study and were used to determine a starting dose for additional phase I studies (stage 2). The model-based design was compared to a conventional study design regarding safety (number of dose-limiting toxicities (DLTs)), efficiency (number of patients treated with a dose below the recommended dose) and effectiveness (precision of dose selection). Retrospective data of the investigational anticancer drug indisulam were used to show the applicability of the model-based design. Results The model-based design was as safe as the conventional design (median number of DLTs = 3) and resulted in a reduction of the number of patients who were treated with a dose below the recommended dose (−27%, power 89%). A post-hoc model-based determination of the recommended dose for future phase II studies was more precise than the conventional selection of the recommended dose (root mean squared error 8.3% versus 30%). Conclusions A two-stage model-based phase I design is safe for anticancer agents with dose-limiting myelosuppression and may enhance the efficiency of dose escalation studies by reducing the number of patients treated with a dose below the recommended dose and by increasing the precision of dose selection for phase II evaluation

Positive charge trapping phenomenon in n-channel thin-film transistors with amorphous alumina gate insulators

No description supplie